Table 2.
Changes from preoperative to the 3- and 12-month follow-up for PDSS, Scopa-Aut, PDQ-39, MDS-UPDRS I–IV, and LEDD.
| Preoperative | 3 months | 12 months | p | |
|---|---|---|---|---|
| PDSS, n | 58 | 49 | 52 | |
| PDSS total | 93.8 (21.3) | 110.0 (21.7) | 107.3 (21.3) | <0.001b |
| Overall quality of night’s sleep (Q1) | 5.0 (2.8) | 6.5 (2.9) | 6.2 (2.8) | <0.001b |
| Sleep onset and maintenance insomnia (Q2, Q3) | 10.9 (4.1) | 12.9 (4.8) | 12.0 (4.4) | 0.007 |
| Nocturnal restlessness (Q4, Q5) | 11.5 (5.2) | 14.1 (4.9) | 13.0 (5.9) | 0.003b |
| Nocturnal psychosis (Q6, Q7) | 16.8 (3.4) | 17.5 (2.7) | 16.4 (4.9) | 0.120 |
| Nocturia (Q8, Q9) | 11.7 (3.8) | 12.4 (4.2) | 12.5 (4.0) | 0.055 |
| Nocturnal motor symptoms (Q10–Q13) | 26.2 (8.9) | 32.4 (6.0) | 33.1 (6.4) | <0.001b |
| Sleep refreshment (Q14) | 5.2 (3.0) | 6.3 (3.0) | 6.0 (3.1) | 0.041 |
| Daytime dozing (Q15) | 6.5 (3.3) | 8.0 (2.4) | 7.6 (3.2) | <0.001b |
| Scopa-Aut, n | 58 | 54 | 53 | |
| Scopa-Aut total | 16.9 (8.2) | 13.0 (6.8) | 15.2 (8.4) | <0.001b |
| Gastrointestinal (Q1–7) | 5.0 (3.3) | 4.2 (2.9) | 4.8 (3.6) | 0.059 |
| Urinary (Q8–13) | 5.8 (3.7) | 4.4 (2.7) | 5.2 (3.7) | 0.054 |
| Cardiovascular (Q14–16) | 0.8 (1.1) | 0.6 (0.9) | 0.6 (1.0) | 0.172 |
| Thermoregulatory (Q17–21) | 3.2 (2.5) | 1.8 (1.8) | 2.2 (2.3) | <0.001b |
| Pupillomotor (Q19) | 0.7 (0.8) | 0.5 (0.6) | 0.7 (0.9) | 0.059 |
| Sexual (Q22–25) | 1.4 (1.8) | 1.5 (1.8) | 1.6 (2.0) | 0.622 |
| PDQ, n | 59 | 51 | 53 | |
| PDQ-39 | 27 (12) | 18 (13) | 20 (15) | <0.001 |
| MDS-UPDRS, n | 60 | 56 | 55 | |
| MDS-UPDRS I | 11.3 (6.1) | 8.7 (5.8) | 9.0 (5.7) | <0.001 |
| MDS-UPDRS II | 16.8 (7.3) | 10.9 (6.5) | 11.5 (6.7) | <0.001 |
| MDS-UPDRS III off | 49 (13) | 19 (10) | 20 (9) | <0.001 |
| MDS-UPDRS III on | 14 (9) | 12 (7) | 12 (7) | <0.001 |
| MDS-UPDRS IVa | 9.6 (3.5) | 2.5 (3.0) | 2.6 (3.7) | <0.001 |
| LEDD | 1301 (441) | 689 (373) | 639 (328) | <0.001 |
Mean (SD) are shown for all patients who had complete scores at each time point.
Significance of changes (p value presented) was tested with one-way repeated-measures ANOVA in subjects with values at all three time points; for PDSS n = 44 and for Scopa-Aut n = 51.
aFriedman test.
bSignificant also after Bonferroni correction (for PDSS significance level p < 0.006, for Scopa-Aut significance level p < 0.007).